[Observation of the therapeutic and characteristic effects of terlipressin on refractory cirrhotic ascites]

What Was Tested

The paper reports a study of Terlipressin, published as a controlled clinical trial.

Objective: To observe the therapeutic effect of terlipressin on refractory ascites (RA) in cirrhosis, and its role and impact on acute kidney injury (AKI).

The LSD method of one-way ANOVA was used to compare the two groups.

Mann-Whitney rank- sum test was used to compare the data of non-normal distribution between the two groups.

Why It Was Studied

Methods: A non-randomized controlled clinical trial data of 111 hospitalized cases of liver cirrhosis accompanied with RA was collected from Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Zhongshan Hospital of Hubei Province, The First Affiliated Hospital of Zhengzhou University, The First Affiliated Hospital of Medical School of Zhejiang University, and People's Hospital of Pudong New Area of Shanghai between March 2015 and March 2017. 26 cases of conventional treatment group (control group) were divided into two subgroups: RA without AKI (RA-NAKI) and RA with AKI (RA-AKI), and each subgroup consisted 13 cases.

The treatment duration lasted for 2 weeks with 4 weeks of follow-up.

Who Took Part

The age groups tagged for this paper are children.

Patients with bacterial infection were treated with diuretics, albumin supplementation and antibiotics. 85 cases were presented in terlipressin combined treatment group, of which 27 cases were of RA-NAKI and 58 cases were of RA-AKI.

What Was Measured

Count data were tested by χ (2).

One-way analysis of variance was used for normal distribution data and Kruskal-Wallis H test for non-normal distribution data.

Topics PubMed links to this paper include Acute Kidney Injury, Ascites, China, Liver Cirrhosis, Terlipressin and Vasoconstrictor Agents.

What This Means in Plain Language

This is a controlled clinical trial of Terlipressin.

The publication is from 2019 (Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology), a journal based in China.

More context: the Terlipressin compound page, all human trials.